While certain molecules and blood components can be accurately measured with a small droplet of blood using sophisticated machines, the technology to replace comprehensive blood panels used in routine check-ups is not yet within reach.
The intersection between venture capital and science can result in the over-inflation and downfall of companies. The history of Genentech's incubation and sudden discovery of synthetic insulin is an example of this pattern.
The CEO of Quest Diagnostics, Steve Rusckowski, discusses his company's journey from zero to 40 million dollars in sales in just three years and the challenge of creating a mix of one-time purchases, repeat business, and recurring contracts.
The infrastructure solutions that are urgently needed will not be funded by SoftBank but there's now a growing free market appetite for them as seen in the ballooning entrepreneurship, advancing technology, and pouring capital. These solutions are important for us to accelerate the outcome and emerge victorious in the war.
The speaker discusses how even if a thousand investments fail, hitting one hundred billion dollar company can make up for the losses and mentions potentially successful companies like Air Table, RAPI, Substack, and Clubhouse.
The concept of radical transparency in healthcare can disrupt the industry as it helps in understanding pricing which is a major issue among patients and stakeholders. This could also be applicable in many other industries where trust is becoming an issue.